RetaCalc
Protocol library
SingleApproved OtherMixedModerate confidenceSourced

Thymosin alpha-1

An immune-modulating peptide used in some jurisdictions and studied across highly varied infections, liver disease and immune conditions.

Evidence context, not a personal protocol

Quantities below reproduce their stated source context—label, human study, laboratory work or educational guide. They do not assess suitability, product equivalence or individual risk.

Dosage and protocol evidence

Each card states what the quantities are based on. A third-party or animal schedule is not a validated human dose.

Evidence Gap
Adults in historical chronic hepatitis studies

1.6 mg subcutaneously twice weekly in several disease-specific programmes

The review found mixed hepatitis results and does not support transferring this schedule across indications.

View source
Human Study
Five adults with common variable immune deficiency and depression

1.6 mg subcutaneously daily for one week, then twice weekly for seven weeks

This was a very small open-label proof-of-concept study, not confirmatory evidence.

View source

Evidence summary

An immune-modulating peptide used in some jurisdictions and studied across highly varied infections, liver disease and immune conditions.

Protocol basis

The page reports common disease-specific research schedules while emphasising that regulatory status and evidence vary by jurisdiction and indication.

What remains uncertain

Which patients benefit, how schedules compare, long-term outcomes and applicability to unregulated vials remain uncertain.

Warnings and contraindications

Authorised indications and availability vary substantially by jurisdiction.
Schedules differ by disease, combination therapy and immune status.
Evidence from one infection or immune condition cannot support unrelated uses.